E-cadherin and FGFR3 are risk factors determining prognosis of patients with bladder urothelial carcinoma.

OBJECTIVE

To explore the diagnostic value of the combined detection of E-cadherin and FGFR3 in patients with bladder urothelial carcinoma and their correlation with patient prognosis.

METHODS

The study retrospectively analyzed the case data of 96 patients with bladder urothelial carcinoma treated at the Yixing Guanlin Hospital from June 2018 to June 2020. Tumor tissue of each patient and matched healthy tissue were collected for immunohistochemical staining. Differences in FGFR3 and E-cadherin expression were identified between tumor and healthy tissues. The influence of clinical characteristics on the recurrence was analyzed using a univariate analysis. Then, a multivariate logistic regression analysis was performed to analyze the risk factors for recurrence in patients with bladder urothelial carcinoma. The diagnostic value of FGFR3, E-cadherin and their combination for disease recurrence and prognosis was analyzed. The correlation of FGFR3 and E-cadherin expression with disease recurrence was discussed.

RESULTS

The positive expression of FGFR3 in the cancer tissues was significantly higher than that in the adjacent tissue, while the positive expression of E-cadherin showed the opposite (P<0.05). Logistic regression analysis showed that tumor size, TNM stage, pathological grade, FGFR3 and E-cadherin were risk factors for the recurrence of bladder urothelial carcinoma (P<0.05). The area under the curve of FGFR3 combined with E-cadherin in evaluating prognosis and recurrence was 0.957. Correlation analysis revealed that FGFR3 was significantly and positively correlated with the patients' prognostic recurrence while E-cadherin was negatively correlated with it.

CONCLUSION

FGFR3 and E-cadherin are risk factors affecting the prognosis of patients with bladder urothelial carcinoma, and they are associated with the outcome of bladder cancer.